Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial-Reference-Cited by-同舟云学术

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

Published:2022-11 Issue:11 Volume:9 Page:e822-e832
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Lonial Sagar,Popat Rakesh,Hulin Cyrille,Jagannath Sundar,Oriol Albert,Richardson Paul G,Facon Thierry,Weisel Katja,Larsen Jeremy T,Minnema Monique C,Abdallah Al-Ola,Badros Ashraf Z,Knop Stefan,Stadtmauer Edward A,Cheng Yiming,Amatangelo Michael,Chen Min,Nguyen Tuong Vi,Amin Alpesh,Peluso Teresa,van de Donk Niels W C J

Publisher

Elsevier BV

Subject

Hematology

Reference30 articles.

1. Multiple myeloma;van de Donk;Lancet,2021

2. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy;Gandhi;Leukemia,2019

3. Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices;Jagannath;Expert Rev Hematol,2016

4. The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies;Hari;J Geriatr Oncol,2018

5. Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis;Pick;Eur J Haematol,2018

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Maintenance Therapy in the Treatment of Newly Diagnosed Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma;Cancers;2024-08-23

3. The emerging role of melflufen and peptide-conjugates in multiple myeloma;Current Opinion in Oncology;2024-08-22

4. A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma;eJHaem;2024-08

5. Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide;Expert Review of Hematology;2024-07-27